… Monte Carlo simulation demonstrated rivaroxaban was cost–… suggests that rivaroxaban
therapy may be a cost–effective … model to evaluate the cost–effectiveness of rivaroxaban 20 mg 1 …

… Our results showed that the substantially higher medication costs of rivaroxaban were offset
… Future health economic studies on novel oral anticoagulants should evaluate the cost …

… cost-effectiveness comparison between 2 of the 4 therapies for stroke prevention in patients
in the United States with atrial fibrillation… to estimate the long-term cost-effectiveness of stroke …

… use of rivaroxaban may be cost-saving or cost-neutral as compared to warfarin. The overall
nondrug lower costs for rivaroxaban users suggest that treatment with rivaroxaban results in …

Objective The objective was to assess the real-world cost-effectiveness of rivaroxaban,
versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation (AF) …

… costs, and incremental cost-effectiveness ratios (ICER). The aim of our investigation was to
examine cost-utility for current German drug market costs … s RE-LY, rivaroxaban’s ROCKET AF…

… Background and Objectives: Rivaroxaban … atrial fibrillation (AF) and is associated with a
lower rate of intracranial hemorrhage (ICH). We assessed the cost-effectiveness of rivaroxaban …

… rivaroxaban is related to an additional cost of $27,498 per QALY gained over warfarin,
indicating that rivaroxaban may be a cost-… Finally, a recently published cost-effectiveness study …

… of rivaroxaban is associated with 5.69 QALYs at a cost of $66,075 per patient, while warfarin
produced 5.22 QALYs with costs … dominated by rivaroxaban in 99.4% of 10,000 simulations. …

… costs of rivaroxaban were partially offset by savings in warfarin administration costs and savings
in costs … The use of rivaroxaban in this therapeutic indication would help to decrease the …